Erythropoietin Drugs Market Size to Reach US$ 13.8 Billion 2022-2027 - IMARC Group

According to the latest report by IMARC Group "Erythropoietin Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", The global erythropoietin drugs market size reached US$ 9.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 13.8 Billion by 2027, exhibiting a growth rate (CAGR) of 5.75% during 2022-2027.

Erythropoietin (EPO) represents a hormone secreted by kidneys, which stimulates red blood cell (RBC) production. Its deficiency may cause low hemoglobin levels and various other medical conditions. EPO drugs or EPO stimulating agents (ESAs) are produced synthetically by applying recombinant Deoxyribonucleic acid (DNA) technology. They are typically administered through the intramuscular route and absorbed by the bloodstream to prompt RBC production. EPO drugs are commonly given to patients undergoing chemotherapy, chronic renal failure, antiviral drug therapy, etc.

Request for a free sample copy of this report: https://www.imarcgroup.com/erythropoietin-drugs-market/requestsample

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Erythropoietin Drugs Market Trends and Drivers:

The increasing number of individuals with anemia due to cancer, chronic kidney disease (CKD), prematurity, etc., is primarily driving the demand for EPO drugs. Moreover, these drugs are also used for treating zidovudine among patients with human immunodeficiency virus (HIV) infection. Additionally, with the growing geriatric population across the globe, there is an elevating requirement for surgical interventions, which is encouraging product use for minimizing allogeneic blood transfusions after surgical procedures. Furthermore, the rising utilization of ESAs as a novel therapeutic agent for research purposes is also expanding their applications in treating numerous conditions, such as spinal cord injury (SCI), diabetes, acute kidney injury (AKI), etc. Apart from this, the increasing popularity of minimally invasive (MI) procedures is anticipated to further bolster the EPO drugs market over the forecasted period.

Breakup by Drug Class:

Biologics
Biosimilars

Breakup by Product Type:

Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others

Breakup by Application:

Hematology
Kidney Disorder
Cancer
Others

Breakup by End User:

Hospitals
Homecare
Specialty Clinics
Others

Market Breakup by Region:

North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa

Competitive Landscape with Key Player:

Amgen Inc.
Biocon Limited
Dr. Reddy's Laboratories Ltd.
F. Hoffmann-La Roche AG
Intas Pharmaceuticals Ltd.
Johnson & Johnson
LG Chem Ltd.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd.

Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/erythropoietin-drugs-market

Note: We are updating our reports, if you want the report with the latest primary and secondary data (2023-2028) including industry trends, market size and competitive landscape, etc. click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Contact US

IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.